Joseph Turner
There is a new member of the board at Sophiris Bio in the form of Joseph Turner.
Turner has over 25 years of financial management experience in the biotech and pharmaceutical industries, having served at companies including Myogen (sold to Gilead), Centaur Pharmaceuticals.
“Joe brings extensive experience to our Board of Directors in strategic planning, finance, investment banking and investor relations in the biotech industry,” said Randall Woods, President and CEO of Sophiris.
Sophiris is a biopharmaceutical company developing a clinical-stage, targeted treatment for the symptoms of benign prostatic hyperplasia. For more news concerning the biopharma industry, check out our new sister publication Biopharma-Reporter.com.